32 results about "Substrate analog" patented technology

The present invention relates to improved methods of detecting a target using a labeled substrate or substrate analog. The methods comprise reacting the substrate or substrate analog in an enzyme-catalyzed reaction which produces a labeled moiety with independently detectable signal only when such substrate or substrate analog reacts. The present invention, in particular, describes methods of detecting a nucleic acid in a sample, based on the use of terminal-phosphate-labeled nucleotides as substrates for nucleic acid polymerases. The methods provided by this invention utilize a nucleoside polyphosphate, dideoxynucleoside polyphosphate, or deoxynucleoside polyphosphate analogue which has a colorimetric dye, chemiluminescent, or fluorescent moiety, a mass tag or an electrochemical tag attached to the terminal-phosphate. When a nucleic acid polymerase uses this analogue as a substrate, an enzyme-activatable label would be present on the inorganic polyphosphate by-product of phosphoryl transfer. Cleavage of the polyphosphate product of phosphoryl transfer via phosphatase leads to a detectable change in the label attached thereon. When the polymerase assay is performed in the presence of a phosphatase, there is provided a convenient method for real-time monitoring of DNA or RNA synthesis and detection of a target nucleic acid.

This invention provides a direct method for monitoring bacterial transglycosylase activity using labeled substrates produced by chemo-enzymatic synthesis wherein the labels are selected to permit the detection of both polymeric and non-polymeric products simultaneously, either directly or following the separation of product from starting material. The invention promotes the discovery of new antibiotics with activity against bacterial transglycosylases by a) laying the groundwork for structural analysis of purified, active transglycosylase (which permits structure-based design); and b) providing an assay that can be used to screen for inhibitors.

The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.

The present invention relates to the use of creatine compounds including cyclocreatine and creatine phosphate for treating or preventing a metabolic disorder consisting of hyperglycemia, insulin dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, diabetes related diseases in a patient experiencing said disorder. The creatine compounds which can be used in the present method include (1) analogues of creatine which can act as substrates or substrate analogues for the enzyme creatine kinase; (2) compounds which can act as activators or inhibitors of creatine kinase; (3) compounds which can modulate the creatine transporter (4) N-phosphocreatine analogues bearing transferable or non-transferable moieties which mimic the N-phosphoryl group. (5) compounds which modify the association of creatine kinase with other cellular components.

The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.

The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.

Embodiments of the present invention are directed to sensitive, specific, and commercially feasible assays for transferase activity. Various embodiments of the present invention include artificial, multifunctional substrates specific for particular transferases that are chemically altered by the transferases to produce easily detectable, modified, multifunctional substrates. In one class of embodiments, the artificial, multifunctional substrate comprises a small-molecule-substrate component, or small-molecule-substrate-analog component, linked by a linking component to a biopolymer-substrate-mimetic or biopolymer-substrate-analog component. At least two, generally well-separated reporter moieties are included in the artificial, multifunctional substrate. The transferase, for which the artificial, multifunctional substrate is designed to serve as an assay reagent, catalyzes a generally covalent modification of the artificial, multifunctional substrate to produce a modified, artificial, multifunctional substrate reaction product in which the two reporter moieties are closely positioned to one another. When closely positioned to one another, the reporter moieties are detectable by one of various instrumental techniques.

This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid and related compounds. Crystal structure shows that the compounds don't bind directly to the catalytic site of the enzyme, and so are not defined simply as substrate analogs. Instead, they create a pocket by induced fit, resulting a powerful and specific inhibitory effect on FBA activity.

The invention discloses a sarcosine oxidase affinity medium and a method for synthesizing and purifying sarcosine oxidase, which belong to the technical field of biologic engineering. The sarcosine oxidase affinity medium disclosed by the invention is prepared by connecting a sarcosine oxidase affinity ligand with a chromatography medium; preferably, the sarcosine oxidase affinity ligand is a substrate analog 4-amino pyrrole-2-carboxylic acid, and the chromatography medium is Sepharose or poly-chitosan; the invention further provides a synthesis method of the sarcosine oxidase affinity medium, and a method for purifying the sarcosine oxidase in a large scale by using the sarcosine oxidase affinity medium. By utilizing the sarcosine oxidase affinity medium disclosed by the invention, the sarcosine oxidase can be rapidly separated and purified in a large scale, and a sarcosine oxidase pure product can be obtained under the condition of one step affinity chromatography; and the whole purification step is short in time, the protein and activity recovering rate is high, and thus being applicable to large-scale popularization and application.

General methods for monitoring the activity of MurG, a GlcNAc transferase involved in bacterial cell wall biosynthesis, is disclosed. More particularly, the synthesis of simplified substrate analogs of Lipid I (the natural substrate for MurG), which function as acceptors for UDP-GlcNAc in an enzymatic reaction catalyzed by MurG, is described. Assays using the substrate analogs of the invention are further disclosed, which are useful for identifying a variety of other substrates, including inhibitors of MurG activity, for facilitating mechanistic and/or structural studies of the enzyme and for other uses. High throughput assays are also described.

The instant invention provides methods, reagents, and computational tools for designing non-natural substrate analogs for enzymes, especially for designing unnatural amino acid analogs for aminoacyl tRNA Synthetases (AARSs), such as the Phe tRNA Synthetase. The instant invention also provides methods to incorporate unnatural amino acid analogs, especially those with interesting functional groups, into protein products to generate proteins of modified or novel functions.

The substrate and subsite specificity of the catalytically active enzyme was determined by measuring the initial hydrolysis rate of the substrate using MALDI-TOF/MS. In addition, memapsin subsite specificity was determined by probing the inhibitor library with memapsin2 and detecting bound memapsin2 with a memapsin2 antibody and alkaline phosphatase-conjugated secondary antibody. Substrate and subsite specificity information can be used to design analogs of natural memapsin2 substrates capable of inhibiting memapsin2 function. Substrate analogs are based on peptide sequences related to the native peptide substrate of memapsin2. Substrate analogs contain at least one analog whose amide bond cannot be broken by memapsin2. A synthetic method for analogues containing isosteric substrates at key amino acid residue positions has been developed, and more than 70 substrate analogues have been synthesized, including MM1-005, MM1-012, MM1-017, MM1- 018, MM1-025, MM1-026, MM1-037, MM1-039, MM1-040, MM1-066, MM1-070 and MM1-071 correspond to recombinant pro-memapsin2 with inhibition constants in the range of 1.4-61.4×109M . These inhibitors are useful in the diagnosis, treatment and/or prevention of Alzheimer's disease.

The present disclosure provides a composition for enhancing effect of an inhibitor in inhibiting NAD⁺/NADP⁺ or NADH/NADPH dependent enzymes. The inhibition of the NAD⁺/NADP⁺ or NADH/NADPH dependent enzymes such as Enoyl-ACP reductase (ENR) by the composition of the present disclosure serves as a target for treating malaria and other infectious diseases. The present disclosure provides composition comprising inhibitor and polyphenol, wherein the polyphenol was found to enhance the inhibitory activity of the inhibitor. The present disclosure provides method for treating an infectious disease comprising administering an effective amount of the composition of the present disclosure to patients in need thereof. The present disclosure further provides a method for identifying a compound that enhances the effect of the inhibitor, a method of determining the antimalarial activity of a compound and use of polyphenol as a bioenhancer that enhances effect of an inhibitor for inhibiting NAD⁺/NADP⁺ or NADH/NADPH dependent enzymes. The present disclosure provides a composition comprising inhibitor and a polyphenol wherein the polyphenol enhances effect of the inhibitor for inhibiting aldose reductase for treating complications of diabetes that include diabetic retinopathy, cataract neuropathy and neural complication.

Systems and methods of coding for and isolating a fusion protein are provided. The fusion protein may be expressed by a DNA sequence and comprise an adenylate kinase linked by its carboxy-terminus to a biologically active polypeptide or protein. Later processing steps include isolating the biologically active polypeptide or protein via affinity elution of the fusion proteins with substrate analog of adenylate kinase.

A method of improving resistance to a substrate analog of nitric acid in a microalga, containing

deleting a gene encoding the following protein (A) or (B) present in the genome of the microalga, or downregulating expression of a gene encoding the following protein (A) or (B):

(A) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 41; and

(B) a protein consisting of an amino acid sequence having 70% or more identity with the amino acid sequence of the protein (A), and having nitrate transporter activity.